Imagine training a specialized army of immune cells to find and destroy cancer, but instead of building a custom army for every single patient, we create a universal one that works for anyone. This project uses a special type of cell from umbilical cords that doesn't attack itself or the patient's healthy system. It targets two specific markers on cancer cells to ensure the 'soldiers' hit the right target without causing collateral damage.
Current T-cell leukemia treatments often fail because the therapy attacks both the cancer and the healthy immune cells, or the patient is too sick to provide their own cells for treatment. This leads to a mortality rate exceeding 90% for relapsed cases.
A scalable platform for allogeneic gamma delta T-cells and an optimized protocol for their in vitro expansion and transduction.
If you are a Cell Therapy Developer dealing with the high cost and time of patient-specific CAR-T manufacturing — this project developed a proprietary platform of CORD-GDT cells that provides a ready-to-use, off-the-shelf alternative. This removes the need to harvest cells from multi-treated patients.
If you are an Oncology Drug Manufacturer dealing with the 90% mortality rate of R/R T-ALL patients — this project developed a dual-targeting immunotherapy that avoids the fratricide of CAR-T cells. This offers a potential curative option beyond chemotherapy and stem cell transplants.
If you are a Specialized Cancer Hospital dealing with the toxicities of conventional chemotherapy for leukemia — this project developed a point-of-care treatment using HLA-independent cells. This allows for faster, more cost-effective administration to patients with advanced disease.
By using an allogeneic, off-the-shelf platform of CORD-GDT cells, the project eliminates the expensive and time-consuming process of harvesting and engineering cells from each individual patient. Based on available project data, this creates a more cost-effective immunotherapeutic alternative.
Yes, the project specifically aims to develop a scalable platform for the in vitro expansion and transduction of these cells. The goal is to provide ready-to-use effector cells for point-of-care treatment.
The project utilizes a proprietary platform of CORD-GDT cells. Based on available project data, the consortium is maturing and scaling up this proprietary technology.
The project has already outlined an interim regulatory plan as part of its early work performed between March 2023 and March 2024.
The project period runs from 2023-04-01 to 2026-07-31, with initial expansion protocols and characterization completed in the first year.
The consortium is lean and agile, consisting of 3 partners across 2 countries (Spain and Portugal). It is heavily driven by SMEs, with 2 out of 3 partners being small-to-medium enterprises, resulting in an industry ratio of 33%. The leadership by OneChain Immunotherapeutics S.L. suggests a strong commercial drive to transition the proprietary CORD-GDT platform from research to a scalable product.
Contact OneChain Immunotherapeutics S.L. in Spain
Contact us to explore licensing opportunities for the CORD-GDT proprietary platform.
